You are here

• Home
• Diseases & Conditions
• All Diseases and Conditions

• OSKIRA-ABPM: A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Effect of Fostamatinib 100 mg Twice Daily on 24-hour Ambulatory Blood Pressure in Patients with Rheumatoid Arthritis

Disease

rheumatoid arthritis

Drug Name

Fostamatinib Disodium

Generic Name

Fostamatinib

Sponsor

AstraZeneca

Drug Status

In Development

Phase

II

Start Date

Apr 12, 2012

Study Name

Oskira ABPM

Study Id

D4300C00033

ClinicalTrials.gov ID

NCT01563978

Recruiting Status

Closed

Protocol Status

Not Available

Report Status

Not Available

Page tools

• Print
• Bookmark this page